A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Trandolapril and Verapamil

Angiotensin Converting Enzyme Inhibitor class · 1 generic manufacturer · 4 ANDAs filed at FDA.

First FDA approval2015-02-25
Generic availableYes · 1 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema8 entries indexed · 4 visible
What is Trandolapril and Verapamil used for?

Trandolapril and Verapamil is a Angiotensin Converting Enzyme Inhibitor medication tracked in Medicare Part D.

Is there a generic for Trandolapril and Verapamil?

Yes. 4 ANDAs filed at FDA, 1 generic manufacturers currently shipping.

How much does my plan pay for Trandolapril and Verapamil?

NADAC pricing data not currently available for this drug.

Is Trandolapril and Verapamil on the FDA shortage list?

No. Trandolapril and Verapamil is not currently on the FDA Drug Shortage Database.

4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Angiotensin Converting Enzyme Inhibitor4 alternatives in D1
01
Captopril
Angiotensin Converting Enzyme Inhibitor
$0.138Lowest NADAC
7Generic mfrs
$7.1MCY24 Part D spend
Compare →
02
Ramipril
Brand: Vostally
$0.053Lowest NADAC
8Generic mfrs
$27.4MCY24 Part D spend
Compare →
03
Trandolapril
Angiotensin Converting Enzyme Inhibitor
$0.190Lowest NADAC
3Generic mfrs
$2.0MCY24 Part D spend
Compare →
04
Trandolapril Tablets
Brand: Trandolapril
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (4 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.